Transthyretin Amyloid Cardiomyopathy

• FDA approval · 2024-11-22
  FDA Approved: ATTRUBY — Original Application (BridgeBio Pharma, Inc.)

  The FDA approved ATTRUBY (acoramidis hydrochloride) from BridgeBio Pharma as a new treatment for transthyretin amyloid cardiomyopathy.

• FDA approval · 2021-06-01
  FDA Approved: VYNDAMAX — Supplemental Application (Pfizer Laboratories Div Pfizer Inc)

  FDA approved a supplemental application for VYNDAMAX (tafamidis) submitted by Pfizer Laboratories Div Pfizer Inc.